<|begin_of_text|><|begin_of_text|><|begin_of_text|>Femara belongs to the class of drugs called aromatase inhibitors. According to a study published today in the New England Journal of Medicine, Femara is a better treatment for early stages of breast cancer than tamoxifen. Femara<wm> contains a small molecule that blocks and inhibits the activity of the hormones estrogen and estrogen. These hormones stimulate the growth of estrogen-sensitive cancers. We are often prescribed this drug to treat or delay the growth of estrogen receptor-positive cancers, such as hormone receptor-positive breast cancer.
In a randomized controlled study, a group of approximately 2,900 participants were studied to compare the effectiveness and toxicity of two different treatments for early breast cancer. Half of the women in each treatment arm received a medication called a small</wm> molecule inhibitor called Tamoxifen, while the other half received Femara. Over time, the researchers